PE20090772A1 - Derivados de bencimidazol - Google Patents

Derivados de bencimidazol

Info

Publication number
PE20090772A1
PE20090772A1 PE2008001105A PE2008001105A PE20090772A1 PE 20090772 A1 PE20090772 A1 PE 20090772A1 PE 2008001105 A PE2008001105 A PE 2008001105A PE 2008001105 A PE2008001105 A PE 2008001105A PE 20090772 A1 PE20090772 A1 PE 20090772A1
Authority
PE
Peru
Prior art keywords
methylpiperidin
alkyl
compounds
benzimidazol
halo
Prior art date
Application number
PE2008001105A
Other languages
English (en)
Inventor
Christopher Scott Jones
GRECA Susan LA
Qifang Li
Lawrence Alan Reifer
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20090772A1 publication Critical patent/PE20090772A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BENCIMIDAZOL DE FORMULA (IIa) DONDE R1 ES HALO, ALQUILO(C1-C6), ALCOXI(C1-C6), CF3, ENTRE OTROS; R2 Y R4 SON CADA UNO H O ALQUILO(C1-C6); R3B ES H, ALQUILO(C1-C6), (CH2)t-ARILO(C6-C12), ENTRE OTROS, EN DONDE t ES DE 0 A 2; R10 ES (CH2)t-ARILO(C6-C12) O (CH2)t-HETEROCICLILO DE 4 A 14 MIEMBROS OPCIONALMENTE SUSTITUIDOS CON CN, HALO, CF3, OCF3, ENTRE OTROS; n ES DE 0 A 4. SON COMPUESTOS PREFERIDOS: 1-[(2R,4R)-2-(1H-BENZIMIDAZOL-2-IL)-1-METILPIPERIDIN-4-IL]-3-(4-CIANOFENIL)UREA, 1-[(2R,4R)-2-(1H-BENZIMIDAZOL-2-IL)-1-METILPIPERIDIN-4-IL]-3-(4-CLOROFENILO), 1-[(2R,4R)-2-(1H-BENZIMIDAZOL-2-IL)-1-METILPIPERIDIN-4-IL]-3-(6-FLUOROPIRIDIN-3-IL)UREA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE CRECIMIENTO CELULAR ANORMAL TAL COMO CANCER
PE2008001105A 2007-06-29 2008-06-27 Derivados de bencimidazol PE20090772A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94728707P 2007-06-29 2007-06-29
US4164508P 2008-04-02 2008-04-02

Publications (1)

Publication Number Publication Date
PE20090772A1 true PE20090772A1 (es) 2009-06-24

Family

ID=40161351

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012000473A PE20121010A1 (es) 2007-06-29 2008-06-27 Derivados de bencimidazol
PE2008001105A PE20090772A1 (es) 2007-06-29 2008-06-27 Derivados de bencimidazol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012000473A PE20121010A1 (es) 2007-06-29 2008-06-27 Derivados de bencimidazol

Country Status (46)

Country Link
US (2) US8148401B2 (es)
EP (1) EP2170860B9 (es)
JP (2) JP4567099B2 (es)
KR (1) KR101143246B1 (es)
CN (1) CN101687841B (es)
AP (1) AP2377A (es)
AR (1) AR067346A1 (es)
AU (1) AU2008272641B2 (es)
BR (1) BRPI0813412B8 (es)
CA (1) CA2690953C (es)
CL (1) CL2008001922A1 (es)
CO (1) CO6160232A2 (es)
CR (1) CR11150A (es)
CU (1) CU23847B1 (es)
CY (2) CY1118650T1 (es)
DK (1) DK2170860T5 (es)
DO (1) DOP2009000278A (es)
EA (1) EA016888B1 (es)
EC (1) ECSP099803A (es)
ES (1) ES2609258T3 (es)
FR (1) FR20C1038I2 (es)
GE (1) GEP20125702B (es)
GT (1) GT200900328A (es)
HK (1) HK1139658A1 (es)
HN (1) HN2008000974A (es)
HR (1) HRP20161562T2 (es)
HU (2) HUE030052T4 (es)
IL (1) IL202420A (es)
LT (2) LT2170860T (es)
MA (1) MA31466B1 (es)
ME (1) ME00962B (es)
MY (1) MY148636A (es)
NI (1) NI200900219A (es)
NL (1) NL301057I2 (es)
NO (1) NO2020027I1 (es)
NZ (1) NZ581889A (es)
PA (1) PA8785401A1 (es)
PE (2) PE20121010A1 (es)
PL (1) PL2170860T3 (es)
PT (1) PT2170860T (es)
RS (1) RS55395B9 (es)
SI (1) SI2170860T1 (es)
TN (1) TN2009000544A1 (es)
TW (1) TWI371451B (es)
UY (1) UY31164A1 (es)
WO (1) WO2009004427A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2170860T5 (en) * 2007-06-29 2017-03-20 Pfizer benzimidazole
WO2010028192A1 (en) 2008-09-03 2010-03-11 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
US8835648B2 (en) * 2009-06-11 2014-09-16 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
WO2011024872A1 (ja) 2009-08-26 2011-03-03 武田薬品工業株式会社 縮合複素環誘導体およびその用途
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
JP5802756B2 (ja) 2010-10-20 2015-11-04 ファイザー・インク スムーズンド受容体モジュレーターとしてのピリジン−２−誘導体
JP5452459B2 (ja) 2010-12-16 2014-03-26 株式会社Ｎｔｔドコモ ホーム基地局及びハンドオーバ方法
DK2680694T3 (en) 2011-02-28 2019-03-25 Biomarin Pharm Inc HISTONDEACETYLASE INHIBITORS
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2684167B1 (en) 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
CA2849820C (en) 2011-09-26 2019-08-27 Merck Patent Gmbh Benzyl piperidine compounds as lysophosphatidic acid (lpa) receptor antagonist
IN2014DN11205A (es) 2012-06-20 2015-10-02 Eutropics Pharmaceuticals Inc
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
US10435364B2 (en) 2013-04-17 2019-10-08 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
WO2015066305A1 (en) 2013-10-30 2015-05-07 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
RU2717564C2 (ru) * 2015-04-24 2020-03-24 Пфайзер Инк. Кристаллические формы 1-((2r,4r)-2-(1h-бензо[d]имидазол-2-ил)-1-метилпиперидин 4-ил)-3-(4-цианофенил)мочевины малеата
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2020164722A (ja) * 2019-03-29 2020-10-08 デクセリアルズ株式会社 接着剤組成物
EP4097093B8 (en) 2020-01-28 2024-02-28 Assia Chemical Industries LTD Processes for the preparation of glasdegib and salt thereof and solid state forms of glasdegib maleate and process for preparation thereof
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
EP4126237B1 (en) 2020-03-26 2024-04-10 LEK Pharmaceuticals d.d. Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
KR20230031285A (ko) 2020-06-26 2023-03-07 라퀄리아 파마 인코포레이티드 레티노이드와 암 치료제의 병용 요법이 효과적인 암 환자를 선별하는 방법 및 레티노이드와 암 치료제의 병용 의약
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1638765A (zh) 2001-07-27 2005-07-13 柯里斯公司 Hedgehog信号转导途径介质、其相关组合物以及应用
IL162851A0 (en) * 2001-12-04 2005-11-20 Actelion Pharmaceuticals Ltd 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
JP2006505570A (ja) 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
WO2005042495A1 (en) 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity
CA2543918A1 (en) 2003-10-28 2005-05-12 Dean Wilson Benzimidazoles useful as modulators of ion channels
CA2587489C (en) * 2004-11-03 2013-12-31 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE102005012875B4 (de) 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
WO2008064830A1 (en) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their pharmaceutical uses
CA2672815A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives for use in treating abnormal cell growth
DK2170860T5 (en) * 2007-06-29 2017-03-20 Pfizer benzimidazole
EP2303275A4 (en) 2008-06-17 2012-05-09 Univ Duke STANDARD RECEPTOR MODULATORS
US8507491B2 (en) 2008-08-25 2013-08-13 Irm Llc Compounds and compositions as hedgehog pathway inhibitors

Also Published As

Publication number Publication date
CO6160232A2 (es) 2010-05-20
BRPI0813412A2 (pt) 2014-12-30
TW200911792A (en) 2009-03-16
UY31164A1 (es) 2009-01-30
LTC2170860I2 (lt) 2022-03-10
NL301057I2 (nl) 2020-09-10
AU2008272641A1 (en) 2009-01-08
DK2170860T5 (en) 2017-03-20
CA2690953C (en) 2012-10-02
HUS2000031I1 (hu) 2020-09-28
TN2009000544A1 (fr) 2011-03-31
MY148636A (en) 2013-05-15
CU20090225A7 (es) 2012-02-15
PE20121010A1 (es) 2012-08-06
RS55395B1 (sr) 2017-04-28
HN2008000974A (es) 2011-01-24
DK2170860T3 (en) 2017-01-09
HUE030052T4 (en) 2017-06-28
AR067346A1 (es) 2009-10-07
AP2009005089A0 (en) 2009-12-31
CU23847B1 (es) 2012-10-15
JP4567099B2 (ja) 2010-10-20
HRP20161562T1 (hr) 2016-12-30
US20120157495A1 (en) 2012-06-21
JP2010280693A (ja) 2010-12-16
TWI371451B (en) 2012-09-01
EA200971104A1 (ru) 2010-06-30
BRPI0813412B8 (pt) 2021-05-25
FR20C1038I2 (fr) 2021-08-13
MA31466B1 (fr) 2010-06-01
LTPA2020528I1 (lt) 2020-09-25
CL2008001922A1 (es) 2009-01-02
KR101143246B1 (ko) 2012-05-18
NL301057I1 (nl) 2020-07-22
EP2170860A2 (en) 2010-04-07
EP2170860B1 (en) 2016-11-02
DOP2009000278A (es) 2009-12-31
WO2009004427A2 (en) 2009-01-08
PA8785401A1 (es) 2009-01-23
HUE030052T2 (hu) 2017-04-28
NI200900219A (es) 2010-03-11
US8431597B2 (en) 2013-04-30
JP2010531869A (ja) 2010-09-30
EA016888B1 (ru) 2012-08-30
HRP20161562T2 (hr) 2017-04-21
ECSP099803A (es) 2010-01-29
PT2170860T (pt) 2017-01-04
HK1139658A1 (en) 2010-09-24
BRPI0813412B1 (pt) 2020-01-21
US20090005416A1 (en) 2009-01-01
AU2008272641B2 (en) 2013-08-29
FR20C1038I1 (es) 2020-10-02
NZ581889A (en) 2011-05-27
ME00962B (me) 2012-06-20
CR11150A (es) 2010-02-08
EP2170860B9 (en) 2017-02-22
CN101687841B (zh) 2013-07-10
PL2170860T3 (pl) 2017-05-31
CN101687841A (zh) 2010-03-31
CY2020028I1 (el) 2020-11-25
RS55395B9 (sr) 2020-01-31
IL202420A0 (en) 2010-06-30
KR20100028120A (ko) 2010-03-11
LT2170860T (lt) 2017-01-10
WO2009004427A3 (en) 2009-06-04
SI2170860T1 (sl) 2017-01-31
IL202420A (en) 2014-05-28
CY1118650T1 (el) 2017-07-12
AP2377A (en) 2012-03-07
CA2690953A1 (en) 2009-01-08
NO2020027I1 (no) 2020-08-11
US8148401B2 (en) 2012-04-03
CY2020028I2 (el) 2020-11-25
GEP20125702B (en) 2012-12-10
ES2609258T3 (es) 2017-04-19
GT200900328A (es) 2011-08-29

Similar Documents

Publication Publication Date Title
PE20090772A1 (es) Derivados de bencimidazol
PE20090952A1 (es) Compuestos de pirazol moduladores de raf
PE20110547A1 (es) Compuestos de isoindolina con actividad anticancerigena
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20190175A1 (es) Compuestos de pirrolotriazina como inhibidores de tam
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20081882A1 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa
PE20211700A1 (es) Compuesto heterociclico y su uso
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
PE20140185A1 (es) Derivados de heteroarilpiperidina y piperazina como fungicidas
PE20070490A1 (es) Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento

Legal Events

Date Code Title Description
FG Grant, registration